|
Macroprolactinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Prolactin levels normalized in 109 (88.6%) of 123 included macroprolactinoma patients.
|
31770105 |
2020 |
|
Macroprolactinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reducing doses of cabergoline to the lowest that keeps prolactin levels normal prior to withdrawal is proposed to patients with macroprolactinomas who normalize prolactin after > 5 years of treatment and who do not have cavernous sinus invasion.
|
30347396 |
2019 |
|
Macroprolactinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
All patients with macroprolactinomas with prolactin concentrations >10,000 mU/L had at least 1 pituitary hormone deficiency.
|
29455199 |
2018 |
|
Macroprolactinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Only 9% of the respondents believed that prolactin >250 ng/mL could occur in all the following situations as macroprolactinoma, mircoprolactinoma, macroprolactinemia and drug-induced hyperprolactinemia.
|
30352394 |
2018 |
|
Macroprolactinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Menopause may also decrease prolactin levels and even those with macroprolactinomas may consider discontinuing their DA agonist with close follow-up.
|
29177641 |
2018 |
|
Macroprolactinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
At last visit, PRL was similar in both groups of patients [16 ng/ml (4-30) vs. 11 ng/ml (4-25); gPRLomas vs. non-gPRLomas; ns] and tumor size decreased significantly (p<0.001) in both groups of patients.
|
30396208 |
2018 |
|
Macroprolactinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
According to the prolactin (PRL) level and magnetic resonance imaging (MRI) results, the patient was diagnosed with macroprolactinoma and kept stable after taking the regular bromocriptine treatment.
|
30212994 |
2018 |
|
Macroprolactinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We conducted a retrospective multicenter study (Marseille, Paris La Pitie Salpetriere and Nancy, France; Liege, Belgium) including patients with macroprolactinomas (largest diameter: >10 mm and baseline prolactin level: >100 ng/mL) treated by dopamine agonists, and regularly followed (pituitary MRI and prolactin levels) during at least 48 months once normal prolactin level was obtained.
|
28073906 |
2017 |
|
Macroprolactinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
46 and 75 % of respondents favored treatment withdrawal 2-3 years after prolactin normalization in patients with macroprolactinomas and microprolactinomas, respectively whereas 10 % of respondents withdraw treatment after menopause in either case.
|
27783196 |
2017 |
|
Macroprolactinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reduction in pituitary tumour volume and brisk fall in serum prolactin in response to low-dose cabergoline is regularly observed in patients with macroprolactinomas, but the concurrent fall in the plasma ACTH level and hypocortisolism was a pleasant surprise.
|
28784879 |
2017 |
|
Macroprolactinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cabergoline therapy has been reported to achieve normalization of prolactin levels and gonadal function and reduction of tumor volume in >50% of patients with macroprolactinoma.
|
23329574 |
2013 |
|
Macroprolactinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, in the three experimental models of prolactinomas, pituitary size was increased and there was hyperprolactinemia, but PTTG levels followed different patterns.Patients with macroprolactinomas were divided in those in which dopaminergic therapy normalized or failed to normalize prolactin levels (responsive and resistant, respectively).
|
17222350 |
2007 |
|
Macroprolactinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
[Disappearance of the radiographic image of a macroprolactinoma after treatment with bromocriptine].
|
9617019 |
1998 |
|
Macroprolactinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
[A case of prolactinoma presenting with CSF rhinorrhea and CSF otorrhea during bromocriptine therapy].
|
1407345 |
1992 |
|
Macroprolactinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Ultrastructural localization of prolactin in estrogen-induced prolactinoma of the rat pituitary. Experimental models for the human prolactinomas and the effects of bromocriptine.
|
3776530 |
1986 |
|
Macroprolactinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Pituitary apoplexy following chlorpromazine stimulation.
|
718334 |
1978 |